Takeda Pharmaceutical Co. said Tuesday that its experimental dengue vaccine appears to be safe and effective at preventing all four types of the mosquito-borne disease, meeting the main goal of the drugmaker's late-stage clinical trial.
The company said no significant safety concerns have emerged to date with the vaccine called TAK-003.
Takeda did not disclose how the vaccine performed in people who had never been previously exposed to dengue, a group that experienced an increased risk of severe disease with Sanofi SA's Dengvaxia, the world's first dengue vaccine.